Clinical Study
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
Table 3
Biological values at baseline and last follow-up.
| | TIPS () | OCT-LAR () | value |
| | Baseline | | | | | ET-1 (pg/mL) | 5.9 ± 0.5 | 6.1 ± 0.3 | 0.25 | | URO II (pg/mL) | 2399.9 ± 107.8 | 2453.3 ± 77.8 | 0.18 | | NOx (μmol/L) | 64.9 ± 2.7 | 65.5 ± 2.6 | 0.62 | | Last follow-up | | | | | ET-1 (pg/mL) | 5.6 ± 0.4 | 5.7 ± 0.3 | 0.41 | | URO II (pg/mL) | 2344.8 ± 91.9 | 2419.3 ± 103.8 | 0.08 | | NOx (μmol/L) | 67.9 ± 2.6 | 68.5 ± 2.0 | 0.50 |
|
|
